Specifically targeting genomic rearrangements and mutations in tumor cells remains an elusive goal in cancer therapy. Here, we used Cas9-based genome editing to introduce the gene encoding the prodrug-converting enzyme herpes simplex virus type 1 thymidine kinase (HSV1-tk) into the genomes of cancer cells carrying unique sequences resulting from genome rearrangements. Specifically, we targeted the breakpoints of TMEM135-CCDC67 and MAN2A1-FER fusions in human prostate cancer or hepatocellular carcinoma cells in vitro and in mouse xenografts. We designed one adenovirus to deliver the nickase Cas9 D10A and guide RNAs targeting the breakpoint sequences, and another to deliver an EGFP-HSV1-tk construct flanked by sequences homologous to those surrounding the breakpoint. Infection with both viruses resulted in breakpoint-dependent expression of EGFP-tk and ganciclovir-mediated apoptosis. When mouse xenografts were treated with adenoviruses and ganciclovir, all animals showed decreased tumor burden and no mortality during the study. Thus, Cas9-mediated suicide-gene insertion may be a viable genotype-specific cancer therapy.
A r t i c l e s Genome instability and the resulting chromosomal rearrangements and mutations are hallmarks of cancer 1 . Some of these rearrangements reoccur because they either are cancer drivers or provide other evolutionary advantages to cancer cells that carry them. For example, we have recently identified a panel of fusion genes present in most recurrent and lethal prostate cancers 2 . Targeting chromosomal breakpoints that create these common fusion genes would provide a genotype-specific approach to treating human cancers.
One technology that can be used to target specific sequences in the genome is Cas9-based genome editing. Cas9, a component of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) prokaryotic immune system 3 , is a DNA endonuclease that can be targeted to a specific 20-bp DNA sequence by a single guide RNA (sgRNA) 4, 5 . A D10A mutation in the catalytic domain of Cas9 converts it to a nickase that produces single-strand breaks at the target DNA 4 .
Nicking genomic DNA can be used to precisely introduce sequences into a specific genomic locus by using the cellular homology-directed repair (HDR) pathway. Introducing two nicks in proximity (double nicking) in target DNA increases the efficiency of introducing sequences 50-to 1,500-fold 6 over natural homologous-recombination rates, with an off-target rate as low as 1/10,000. Such specificity makes somatic genomic targeting a viable approach in treating human diseases, especially neoplasms carrying fusion genes that do not exist in normal cells.
HSV1-tk phosphorylates thymidine and forms thymidine monophosphate, a building block for DNA synthesis. However, the substrate specificity of HSV1-tk is different from that of its mammalian counterpart in that it also phosphorylates the synthetic nucleoside homolog ganciclovir (prodrug) 7 , which is not recognized by mammalian thymidine kinase. This phosphorylation results in accumulation of ganciclovir monophosphate in mammalian cells that express HSV1-tk after treatment with ganciclovir. Ganciclovir monophosphate is converted to its triphosphate form by two other kinases 8 . Ganciclovir triphosphate blocks DNA synthesis through elongation termination. Mammalian cells negative for HSV1-tk, in contrast, are immune from this effect, owing to their inability to phosphorylate ganciclovir.
In this report, by using Cas9 D10A -mediated genome editing, we successfully inserted HSV1-tk into the chromosomal breakpoints of the fusion genes TMEM135-CCDC67 (official symbol DEUP1) and MAN2A1-FER. Treatment of tumors bearing these chromosome breakpoints with ganciclovir after introduction of HSV1-tk led to cell death in cell culture and to a decrease in tumor size and mortality in mice xenografted with human prostate and liver cancers.
RESULTS

Strategy to insert HSV1-tk into the fusion-gene breakpoint
One recurring fusion gene discovered in prostate cancer is located between the genes encoding transmembrane protein 135 (TMEM135) and coiled-coil domain containing 67 (CCDC67) 2, 9, 10 . The fusion gene is created by a 6-Mb deletion in the region of chromosome 11q14. 2-21. The deletion joins intron 13 of TMEM135 with intron 9 of CCDC67 in chromosome 11 ( Fig. 1a) and creates a unique sequence breakpoint not present in normal tissues, thus providing a unique target in cancer cells for therapeutic intervention.
targeting genomic rearrangements in tumor cells through cas9-mediated insertion of a suicide gene A r t i c l e s To target this joining sequence, we designed two sgRNAs, each complementary to one of the regions flanking the chromosomal breakpoint on opposite strands (Fig. 1b) . These guide RNAs (gRNAs) and a Cas9 D10A sequence were ligated into the VQAd5-CMV shuttle vector and recombined into pAD5 adenovirus to create pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 . To provide a potential lethal gene for targeted cancer cells, cDNA of HSV-1 tk was ligated with EGFP cDNA in frame, thus yielding the chimeric gene EGFP-tk. The chimeric cDNA was promoterless but contained a full open reading frame and ribosome-binding site for independent translation initiation. To provide homologous sequences to engage the HDR pathway, the construct was then ligated with 584 bp of the intron 13 sequence of TMEM135 at the 5′ end and 561 bp of the intron 9 sequence of CCDC67 at the 3′ end. These sequences were subsequently ligated into the PAdlox shuttle vector and recombined into adenovirus, thus yielding pAD-TMEM135 int13 -EGFP-tk-CCDC67 int9 (Fig. 1c) .
Targeting the TMEM135-CCDC67 breakpoint in vitro
To examine whether the designed gRNAs were adequate for recruiting Cas9 to produce DNA breaks at the targeted DNA, in vitro cleavage assays were performed on pCMV-TMEM135 int13 -CCDC67 int9 plasmids with recombinant Streptococcus pyogenes Cas9 and gRNA generated by in vitro transcription. Both gRNA − and gRNA + cleaved the linearized pCMV-TMEM135 int13 -CCDC67 int9 at the correct locations and generated the expected 4,317-bp and 3,206-bp fragments for gRNA − , and 4,414-bp and 3,109-bp fragments for gRNA + (Fig. 2a) .
We next tested whether pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 /pAD-TMEM135 int13 -EGFP-tk-CCDC67 int9 (Ad-TC) could induce integration of EGFP-tk into the TMEM135-CCDC67 breakpoint of the cancer genome. We first artificially introduced a TMEM135-CCDC67 breakpoint into the prostate cancer cell lines PC3 and DU145 by transfecting a pCMV-TMEM135 int13 -CCDC67 int9 plasmid such that the integrated vector would transcribe an RNA TMEM135 intron 13 Stepwise schematic diagram of the genome therapy strategy to introduce EGFP-tk into the breakpoint of TMEM135-CCDC67. The gRNAs are ligated with a Cas9 D10A sequence into the VQAd5-CMV shuttle vector and recombined into the pAd5 virus. Separately, 584 bp of the TMEM135 intron 13 sequence and 561 bp of the CCDC67 intron 9 sequence are designed to sandwich a promoterless EGFP-tk cDNA, which is ligated into the PAdlox shuttle vector and recombined into adenovirus (adv). A splice acceptor and splice donor from exon 14 of TMEM135 are inserted between TMEM135 intron 13 and EGFP-tk, and between EGFP-tk and CCDC67 intron 9, respectively, to allow for proper EGFP-tk RNA splicing. Cells containing the TMEM135-CCDC67 chromosome breakpoint are infected with these recombinant viruses. After Cas9 D10A nicking at the sites corresponding to the gRNA sequences, donor DNA containing EGFP-tk is integrated into the breakpoint region of TMEM135-CCDC67 through homology-directed recombination (HDR). The integrated EGFP-tk is transcribed by the fusion head-gene (TMEM135) promoter in these cells, spliced and translated into the protein product of EGFP-tk, which in turn blocks DNA synthesis by converting ganciclovir (Gan) to ganciclovir triphosphate.
A r t i c l e s containing the TMEM135-CCDC67 breakpoint under control of the CMV IE94 promoter ( Fig. 2b) . Clones of transformed PC3 cells were selected to quantify the copy number of the TMEM135-CCDC67 breakpoint relative to that of the β-actin gene (ACTB) in the genome. A clone (PC3 BP) that was estimated to contain one copy of the TMEM135-CCDC67 breakpoint per genome was selected on the basis of the ratio of TMEM135-CCDC67 RNA to ACTB (~1:4; PC3 cells are hyperploid for the chromosome region containing ACTB) 11, 12 (Supplementary Fig. 1 ). Similar selection was also applied to select a DU145 clone (DU145 BP) containing the TMEM135-CCDC67 breakpoint.
After PC3 BP cells were infected with Ad-TC, EGFP-tk, expression was identified in cells (on the basis of green fluorescence) that also expressed Cas9 D10A -RFP (on the basis of red fluorescence), whereas little EGFP-tk expression was found in cells that had minimal Cas9 D10A -RFP expression ( Fig. 2c,d and Table 1) , thus suggesting that the integration of EGFP-tk into the genome and the expression of EGFP-tk protein were dependent on Cas9 D10A -RFP and the specific gRNAs. Similar findings were also observed in DU145 BP cells. By contrast, neither PC3 nor DU145 cells transformed with pCMVscript displayed substantial expression of EGFP-tk ( Fig. 2c,d and Table 1) , thus suggesting that no integration of EGFP-tk occurred when the TMEM135-CCDC67 breakpoint was absent. These results indicated that integration of EGFP-tk into the breakpoint of TMEM135-CCDC67 by using Cas9 D10A was highly specific and had few off-target integration events.
To examine whether cancer cells expressing EGFP-tk were susceptible to antiherpes drugs such as ganciclovir, PC3 or DU145 cells expressing the TMEM135-CCDC67 breakpoint were infected with Ad-TC. These cells were exposed to various concentrations of ganciclovir. At 0.075 µg/ml of ganciclovir, the killing of PC3 or DU145 cells reached 50% of its maximal level, and at 5 µg/ml, the killing reached a A r t i c l e s peak ( Fig. 3a) . At 5 µg/ml of ganciclovir, apoptosis of PC3 or DU145 cells containing the TMEM135-CCDC67 breakpoint and infected with Ad-TC was clearly visualized ( Fig. 3b and Supplementary Table 1 ). No significant cell death was observed for cells containing no TMEM135-CCDC67 breakpoint, even though the cells were equally infected with these viruses and exposed to high concentrations of ganciclovir (up to 100 µg/ml; Fig. 3a,b) . These findings indicated that the killing of cancer cells by ganciclovir was breakpoint dependent and highly specific.
Partial remission of xenografted tumors by genome targeting
To examine whether such breakpoint-dependent killing of cancer cells might be used as a treatment for cancer, PC3 or DU145 cells containing the TMEM135-CCDC67 breakpoint were xenografted into the subcutaneous regions of SCID mice. The xenografted tumors were allowed to grow for 3 weeks and reached ~700 mm 3 in size. These mice were then infected with Ad-TC (5 × 10 10 plaque-forming units (pfu)) and treated with ganciclovir (80 mg/kg) three times per week through intraperitoneal injection. Mice xenografted with PC3 or DU145 cancer cells containing the TMEM135-CCDC67 breakpoint experienced exponential tumor growth if they were not treated with ganciclovir ( Fig. 4a) . By contrast, when the tumors were treated with both Ad-TC and ganciclovir, the mice experienced up to 30% shrinkage of the tumor volumes. Integration of TMEM135 int13 -EGFP-tk-CCDC67 int9 , expression of EGFP-tk and apoptosis were detected in PC3 or DU145 cells that contained the TMEM135-CCDC67 breakpoint and were treated with the recombinant viruses ( Supplementary  Fig. 2 ). There was no metastasis detected in mice treated with Ad-TC and ganciclovir. However, PC3 or DU145 cells containing no TMEM135-CCDC67 breakpoint exhibited a 33-50% metastasis rate even after treatment with the recombinant viruses and ganciclovir ( Fig. 4b) . Mice xenografted with PC3 or DU145 cells containing the TMEM135-CCDC67 breakpoint and treated with the recombinant viruses and ganciclovir showed no associated mortality, whereas all control treated mice died by the eighth week after tumor cell xenografting (Fig. 4c) .
Targeting the MAN2A1-FER breakpoint in HUH7 cells
Screening of the human hepatocellular carcinoma cell line HUH7 indicated that it expresses MAN2A1-FER, one of the fusion genes that we have previously identified in prostate cancers 3 , and both MAN2A1-FER mRNA and protein were detected in this cell line ( Fig. 5a,b , Supplementary Fig. 3 and Supplementary Table 2 ). A genome breakpoint has been identified between intron 13 of MAN2A1 and intron 14 of FER in HUH7 cells 13 . The chimeric protein has retained an intact tyrosine kinase domain from FER but has lost the SH2 domain that regulates the kinase activity.
To evaluate the applicability of genome therapy targeting of cancer cells with native fusion-gene breakpoints, we designed a pair of gRNAs specific for intron 13 of MAN2A1 and intron 14 of FER (Fig. 5a,c) . The gRNAs and Cas9 D10A sequence were packaged into an adenovirus to create pAD5-Cas9 D10A -gRNA MAN2A1int13 -gRNA FERint14 . A r t i c l e s This recombinant virus was co-infected with a 'donor' recombinant adenovirus containing the sequences flanking the nick sites (pAD-MAN2A1 int13 -EGFP-tk-FER int14 ). This donor virus also contained splicing sequences corresponding to the acceptor of intron 14 of MAN2A1 and the donor of intron 15 of FER, respectively, so that EGPF-tk interrupted the mRNA of MAN2A1-FER. The results indicated that up to 27% of HUH7 cells infected with these viruses expressed EGFP-tk ( Fig. 5d,e ) in vitro, whereas similar infection of HEP3B cells, which were negative for the MAN2A1-FER fusion, with these viruses induced minimal fluorescent-protein expression. When HUH7 cells, which were negative for the TMEM135-CCDC67 fusion, were infected with adenovirus specific for the TMEM135-CCDC67 breakpoint, there was little expression of EGFP-tk ( Fig. 5d,e) . These results confirmed the specificity of our genome targeting. When HUH7 cells were infected with pAD5-Cas9 D10A -gRNA MAN2A1int13 -gRNA FERint14 /pAD-MAN2A1 int13 -EGFP-tk-FER int14 (Ad-MF) and treated with various concentrations of ganciclovir, up to 27% of cells died after treatment with 10 µg/ml of ganciclovir, whereas HEP3B cells infected with the same viruses exhibited minimal cell death even after they were treated with high concentrations of ganciclovir (Fig. 5f) . When HUH7 cells were infected with Ad-TC and treated with ganciclovir, there was no appreciable increase in cell death, thus clearly indicating that cell death induced by ganciclovir was dependent on the MAN2A1-FER breakpoint.
To examine the effectiveness of targeting MAN2A1-FER in vivo, SCID mice were xenografted with HUH7 and HEP3B cells, and treated with recombinant viruses and ganciclovir 2 weeks after the xenografting (average tumor size of 244 mm 3 ). The mice xenografted with HUH7 cells and treated with Ad-MF and ganciclovir experienced up to a 29% decrease in tumor size relative to the peak size and exhibited no notable metastasis or mortality during the observation period of 8 weeks (Fig. 5g-i) . By contrast, the mice xenografted with HUH7 cells treated with ganciclovir and Ad-TC, the adenoviruses specific for the TMEM135-CCDC67 breakpoint absent in the HUH7 cells experienced an average 39-fold increase in tumor size. Four of these five mice had metastasis in the lung and liver, and all five mice died within 40 d after xenografting. Similar rates of death, metastasis and increases in tumor volume also occurred in mice treated with AD-MF and PBS. The tumors were allowed to grow for 3 weeks before the treatment. The indicated drugs were applied through intraperitoneal injections 3 times per week until all the mice receiving the control treatment had died. The tumor volumes were measured weekly. DU145 BP, DU145 cells transformed with pCMV-TMEM135 int13 -CCDC67 int9 ; DU145 CMV, DU145 cells transformed with pCMVscript; Ad-TC, treatment of pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 and pAD-TMEM135 int13 -EGFP-tk-CCDC67 int9 ; Gan, ganciclovir. (b) Mice treated with TMEM135-CCDC67 breakpoint therapy were free of cancer metastasis. (c) Mice treated with TMEM135-CCDC67 breakpoint therapy showed no mortality. Numbers of mice (n) are indicated. Error bars, s.d. Two-tailed log-rank test was performed to determine the P value.
A r t i c l e s
Ad-MF and ganciclovir treatment of mice xenografted with HEP3B, a hepatocellular cancer cell line negative for the MAN2A1-FER fusion was similarly ineffective. These results indicated that the therapeutic targeting of the cancer genome was highly specific and effective.
Fusion-gene breakpoint targeting is highly specific
The fusion-gene breakpoint-targeting approach used here was highly specific, with average functional off-target rates of 1.3% in both PC3 and DU145 cells (EGFP-tk + /Cas9 D10A -RFP + in PC3 CMV or DU145 CMV cells, Table 1 ) and less than 1% for HUH7 (EGFP-tk + /Cas9 D10A -RFP + in HUH7 treated with adeno-TC, Table 1 ) and HEP3B cells (EGFP-tk + /Cas9 D10A -RFP + in HUH7 treated with adeno-MF, Table 1 ). These off-target rates were largely confirmed by quantitative sequencing methods: the off-target rates ranged from <0.1% to 2.5% in 100 million reads, including samples from in vitro tissue culture experiments, xenografted cancers and liver samples from mice A r t i c l e s that were treated with the recombinant viruses ( Supplementary  Tables 3-6 ). On-target integration rates in vitro, on the basis of sequencing, ranged from 15.9% to 25.5%, whereas rates for xenografted tumors ranged from 21.1% to 33.5%. The higher integration rates in xenografted tumors probably reflect repeated application of the recombinant adenoviruses.
DISCUSSION
Chromosome rearrangement and deletion create many cancer-specific fusion genes 10 . These fusions either generate genes that acquire additional functions that drive cancer progression or destroy genes that block the oncogenic progression. TMEM135-CCDC7 is an example of latter, in which the fusion eliminates the open reading frame in the gene encoding CCDC67, a putative cancer suppressor, and truncates 65 amino acids from the C terminus of TMEM135, a protein widely expressed in most tissues but having unknown function. In contrast, the MAN2A1-FER fusion probably belongs to the first category, owing to the elimination of the SH2 domain of FER, thus potentially leading to constitutive activation of the FER tyrosine kinase 13 . The effects of fusion genes on the functions of the related gene products may be dramatic, owing to creation of a new protein or truncation of protein domains 1, 10, 14 . The presence of chromosome-rearrangement-based fusion genes is one of the hallmarks of human malignancies 1,14 , and targeting fusion -breakpoints may be highly cancer-cell specific. The recent advance in precision cleavage of DNA by the bacterial CRISPR-Cas system makes it possible to target specific genome sequences with relatively high efficiency. Our gRNA target designs produced two nicks at different strands 69 bp apart for the TMEM135-CCDC67 breakpoint and 37 bp apart for the MAN2A1-FER breakpoint. It is unlikely that these nicks would generate a double-stranded DNA break. As a result, the related DNA damage is probably repaired through a homologous-recombination process rather than nonhomologous end joining. Our results are consistent with findings from several other studies indicating that CRISPR-Cas-mediated homologousrecombination rates can reach levels of up to 20-30% (refs. [15] [16] [17] .
To our knowledge, this is the first report of the application of CRISPR-Cas-mediated genome editing to specifically target genomic alterations in cancer genomes with a recombination rate sufficient to achieve partial remission of xenograft tumors. The precision specificity and integration rate of EGFP-tk in genome therapy might make it possible to apply this approach to clinical settings. Future developments that enhance the integration rate of the targeting cassette into the genome target site may be helpful in enhancing the efficiency of genome therapy. Notably the donor sequences of the adenoviral GFPtk genome are outside the gRNA target sites, and thus the viruses do not contain target sequences recognizable by gRNA-Cas9 activity. The recombination rate between the two viruses is probably low. In over 300,000 integrated EGFP-tk sequencing reads ( Supplementary  Tables 5-7) , we did not find any reads indicating recombination between EGPFP-tk and Cas9.
The current therapeutic approach to human cancer heavily relies on interception of signaling pathways that drive cancer growth. However, such an approach invariably leads to drug tolerance and resistance to drug treatment as the cancer genome adjusts its gene expression patterns and, through new mutations that bypass the signaling blockade, develops new pathways to support growth. The subsequent application of second-tier chemotherapy may affect both cancer and normal tissues and thus may generally produce poor therapeutic outcomes. The genome approach may have substantial advantages over chemotherapy because it is specific for the cancer genome sequence, and it kills cancer cells regardless of whether the mutations are cancer drivers. It is possible that additional new mutations and fusion genes will be generated under the pressure of cancer therapy. In principle, additional vectors may be designed to target these genomic lesions and might even increase the integration rate, owing to multiple integrations per cell ( Supplementary Table 7 ). It remains to be determined whether such an adaptive strategy might be feasible in the clinic. For cancers comprising multiple populations of cancer cells with several different fusion-gene targets, these targets can be simultaneously targeted through the genome targeting scheme. Furthermore, our approach is not limited to using HSV-tk in the therapeutic cassette but instead can use a wide spectrum of gene devices, such as immunogens from viruses or toxins from plants or bacteria. The well-documented 'bystander' effect of several prodrugs on tumor cell killing may enhance the therapeutic effects of this genome targeting strategy 1 . When necessary, genome targeting can be combined with other cancer therapeutic treatments, such as tumor immunotherapy or signaling-molecule targeting, to achieve better therapeutic results.
In our initial studies, we did not observe appreciable cytotoxic side effects of these recombinant viruses in either cell culture or animal models. The integration of EGFP-tk can be monitored by fluorescence imaging. In addition, in the event of undesired integration at critical locations in the genomes of healthy cells, the integrated EGFP-tk can be retrieved by Cre expression. The recombinant adenoviruses used in the study are defective for replication and self-propagation, and remain episomal in healthy cells 18 . In addition, other carriers, such as nonviral vectors that efficiently transduce the targeting DNA into cancer cells could be used as alternatives to the recombinant adenoviruses, if they are found to be superior in terms of efficiency and safety. Because the chromosome breakpoints for fusion genes may vary among individuals, genome targeting strategies require individualization. The genome approach described here should in principle be applicable to most human cancers carrying fusion genes and should provide improved targeting specificity of the genome editing tools, such that even smaller mutations might become targetable.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS
Materials and vector construction. All cell lines, including PC3 (prostate cancer), DU145 (prostate cancer), HUH7 and HEP3B were purchased from the American Type Culture Collection. PC3 cells were cultured with F12K medium supplemented with 10% FBS (Invitrogen). DU145 and HEP3B cells were cultured with modified Eagle's medium supplemented with 10% FBS (Invitrogen). HUH7 cells were cultured with Dulbecco's modified Eagle's medium supplemented with 10% FBS. The genomes of these cell lines were tested for short tandem repeat (STR) DNA profiles at eight different loci (CSF1PO, D13S317, D16S539, D5S818, D7S820, THO1, TPOX and vWA) of the genomes by PCR with the following sets of primers (CSF1PO, AACCTGAGTCTGCCAAGGACTAGC/ TTCCACACACCACTGGCCATCTTC; D13S317, ACAGAAGTCTGGGAT GTGGA/GCCCAAAAAGACAGACAGAA; D16S539, GATCCCAAGCTCT TCCTCTT/ACGTTTGTGTGTGCATCTGT; D5S818, GGGTGATTTTC CTCTTTGGT/TGATTCCAATCATAGCCACA; D7S820, TGTCATAGTTT AGAACGAACTAACG/CTGAGGTATCAAAAACTCAGAGG; TH01, GTGG GCTGAAAAGCTCCCGATTAT/ATTCAAAGGGTATCTGGGCTCTGG; TPOX, ACTGGCACAGAACAGGCACTTAGG/GGAGGAACTGGGAACCA CACAGGT; and vWA, CCCTAGTGGATGATAAGAATAATCAGTATG/ GGACAGATGATAAATACATAGGATGG ATGG) on 22 April 2016 (latest). The cell lines were deemed authentic because the STR profiles of the cell lines perfectly matched those published by the ATCC. Mycoplasma tests showed negative results as of 10 July 2016. Rabbit polyclonal anti-Cas9 antibodies were purchased from Clontech (632607). Rabbit anti-HSV-1 TK polyclonal antibodies were purchased from Sigma (H6030-200UG). Antibody validation is provided on the manufacturers' websites. An ABC kit was purchased from Vector Labs.
Construction of vectors.
To construct the gRNA expression vector, sequences flanking the breakpoint region of TMEM135-CCDC67 were analyzed, and gRNAs were designed with the DNA 2.0 tool (https://www.dna20.com/ eCommerce/cas9/input/). Both gRNA − and gRNA + were ligated into an Allin-One NickaseNinja vector that also contained Cas9 D10A . The insert was then released by restriction with XbaI and was ligated into a similarly restricted VQAd5 shuttle vector to create VQAd5-Cas9 D10A -gRNA TMEM135int13 -gRNA C-CDC67int9 . The recombinant shuttle vector was then recombined with pAD5 virus to generate pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 through a previously described method 19 . The construction of pAD5-Cas9 D10A -gRNA-MAN2A1int13 -gRNA FERint14 followed a similar procedure. To construct donor DNA recombinant virus for the TMEM135-CCDC67 breakpoint, PCR was performed on pEGFP-N1 with the primers GTACTCACGTAAGCTTTCGC CACCATGGTGAGCAAGG and GACTCAGATGGGCGCCCTTGTACAGC TCGTCCATGCC. The PCR products were restricted with KasI and HindIII, and ligated into the similarly restricted pSELECT-zeo-HSV1tk vector to create pEGFP-HSV1-tk. PCR was performed on the genomic DNA from a sample in which the TMEM135-CCDC67 fusion was discovered, to obtain the intron 13 sequence of TMEM135 with the primers GACTCAGATGGCGGCCGCCTGT ATTCTTTGTTTTACAGATTTGCTGTCAGGGGTTAG ATAGCTTGCCAG and GTACTCACGTAAGCTTGAGCTAACATTACCAATGAGGC. The PCR products were then restricted with NotI and HindIII, and ligated into the similarly restricted pEGFP-tk vector to create pTMEM135 int13 -EGFP-tk. Subsequently, PCR was performed on the genomic DNA from the sample in which the TMEM135-CCDC67 fusion was discovered, to obtain the intron 9 sequence of CCDC67 with the primers GACTCAGATGGCTAGCAGTTC ACTGAGTGTGCCATGC and GTACTCACGTGAATTCCTATTCTGCCT GCTTGCATACCTTTTGTTTTGGTTGCAGTAT AGTGGGCTGAG. The PCR products were then restricted with NheI and EcoRI, and ligated into the similarly restricted pTMEM135 int13 -EGFP-tk vector to create pTMEM135 int13 -EGFP-tk-CCDC67 int9 . The vector was then restricted with EcoR1 and NotI, and ligated into the similarly restricted vector pAdlox to create pAdlox-TMEM135 int13 -EGFP-tk-CCDC67 int9 . The recombinant shuttle vector was then recombined with adenovirus to create pAd-TMEM135 int13 -EGFP-tk-CCDC67 int9 . For construction of pAdlox-MAN2A1 int13 -EGFP-tk-FER int14 , extended long PCR was performed on 1 µg genomic DNA from HUH7 cells with the primers GACTCAGATGGCGGCCGCGAACATCAGAACTGGG AGAGG and GTACTCACGTAAGCTTCAGGAGAATCACTTGAACCCG. The PCR products were then digested with HindIII and Not1, and ligated into the similarly digested pEGFP-tk vector to create pMAN2A1 int13 -EGFP-tk. A synthetic sequence corresponding to the splicing acceptor site of MAN2A1 intron 13-exon 14 (TAATGTTGGTTTTACCAAAAATATAAATGGTTTGCC TCTCAGTAGATAACATTTATC TTTAATAAATTCCCTTCCCTATCTTTTA AAGATCTCTTTTCGAGCACATAT/ TAATATGTGCTCGAAAAGAGATCT TTAAAAGATAGGGAAGGGAATTTATTAAAGAT AAATGTTATCTACTG AGAGGCAAACCATTTATATTTTTGGTAAAACCAACAT) was ligated into ASE1-restricted pMAN2A1 int13 -EGFP-tk. Separately, a PCR was performed on HUH7 genomic DNA with the primers GACTCAGATGGAATTCAAG GTGGAACACAGAAGGAGG and GTACTCACGTGAATTCGATTACTTT AAATAACTCACTTGGCTTCTTGCAGAGGTAGA GCTGAGAGAAG, to generate a 1,984-bp sequence corresponding to intron 14 of FER, including a 31-bp splice-donor-site sequence corresponding to FER exon 15-intron 15. The PCR products were then restricted with EcoR1 and ligated into similarly restricted pMAN2A1 int13 -EGFP-tk-FER int14 to create pMAN2A1 int13 -EGFPtk-FER int14 . The vector was then restricted with NotI and blunt-ended with T4 DNA polymerase. The products were then restricted with XmaI. Separately, pAdlox vector was restricted with HindIII and blunt-ended with T4 DNA polymerase. The products were restricted with XmaI and ligated with the digestion product of pMAN2A1 int13 -EGFP-tk-FER int14 . The recombinant shuttle vector was then recombined with adenovirus to create pAd-MAN2A1 int13 -EGFP-tk-FER int14 . For the construction of the pCMV-TMEM135-CCDC67bp vector, PCR was performed on genomic DNA from a prostate cancer sample that was positive for the TMEM135-CCDC67 fusion, by using the primers GACTCAGATGAAGCTTAAGAGCATGGGCTTTGGAGTC and GTACTC ACGTTCTAGACTGGAATCTAGGACTCTTGGC. The PCR products were then sequenced to confirm the presence of the TMEM135-CCDC67 breakpoint. The PCR products were digested with HindIII and XbaI, and ligated into a similarly digested pCMVscript vector. The construct was subsequently transfected into PC3 and DU145 cells with Lipofectamine 3000. Cells stably expressing TMEM135-CCDC67-breakpoint transcripts were selected by incubation of the transfected cells in medium containing G418 (200 µg/ml).
In vitro Cas9-target cleavage assays. gRNA DNA sequence plus scaffold-DNA sequence for plus or minus DNA strands were amplified from the all-in-one vector with the following primers: GGCCAGTGAATTGTA ATACGACTCACTATAGGGAGGCGGCACTCACTGAGCTCT T TG CC/AAAAAAAGCACCGACTCGGTGCCACTTTTTC for the gRNA + template of TMEM135-CCDC67; GGCCAGTGAATTGTAATACGACTC ACTATAGGGAGGCGGTGTGGAAAGGACGAAAC ACCG/AAAAAAA GCACCGACTCGGTGCCACTTTTTC for the gRNA − template of TMEM135-CCDC67; GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGTA GCATTAAGGGCCCCC TAAGTTTTAGAGCTAGAAATAGCAAG for the gRNA + template of MAN2A1-FER; and GGCCAGTGAATTGTAATACGA CTCACTATAGGGAGGCGGATAGCTAGAAGGTGGAT CACGTTTTAG AGCTAGAAATAGCAAG for the gRNA − template of MAN2A1-FER. The PCR products were in vitro transcribed with an In vitro Transcription Kit from Ambion to obtain gRNA + and gRNA − products. Cleavage assays were performed at 25 °C for 10 min and then at 37 °C for 1 h under the following conditions: 1× Cas9 nuclease reaction buffer, 30 nM gRNA, 3 nM DNA template and 30 nM S. pyogenes Cas9 nuclease. The cleaved DNA was visualized through 1% agarose gel electrophoresis.
Fluorescence-activated cell sorting (FACS) analysis of apoptotic cells.
The assays were as previously described [20] [21] [22] [23] [24] [25] [26] [27] [28] . Briefly, the cells treated with pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 /pAD-TMEM135 int13 -EGFP-tk-CCDC67 int9 or pAD5-Cas9 D10A -gRNA MAN2A1int13 -gRNA FERint14 / pAD-MAN2A1 int13 -EGFP-tk-FER int14 and various concentrations of ganciclovir were trypsinized and washed twice with cold PBS. The cells were then resuspended in 100 µl of annexin binding buffer (Invitrogen) and incubated with 5 µl of phycoerythrin (PE)-conjugated annexin V and 1 µl of 100 µg/ml propidium iodide for 15 min in the dark at room temperature. The binding assays were terminated by addition of 400 µl of cold annexin binding buffer. FACS analysis was performed with a BD-LSR-II flow cytometer. The fluorescence-stained cells were analyzed at 533-nm fluorescence emission (FL2). The negative control, comprising cells without PE in the incubation medium, was used to set the background for the acquisition. UV-treated cells were used as a positive control for apoptosis. For each acquisition, 10,000 to 20,000 cells were sorted on the basis of the fluorescence color of the cells. WinMDI 2.9 software (freeware from J. Trotter; http://www.cyto.purdue.edu/ flowcyt/software/Winmdi.htm/) was used to analyze the data. For HUH7 and HEP3B FACS analysis, similar procedures were performed, except that the cells were treated with 1 µM scr-7 along with viral infection to improve genome editing efficiency 29 .
Tumor growth and spontaneous metastasis. The sample size used for the tumor xenografting analysis was based on power analysis, assuming 90% survival for treated animals and 10% for control-treated animals. All experiments were performed on 3-week-old male SCID mice, to ensure relevance to prostate cancer. No randomization was done, owing to the inbred nature of the SCID mice. The researchers were partially blinded in the animal study: researchers knew the treatment reagents, but were blinded to the xenografted cancers. The xenografting procedure was as described previously [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] . Briefly, approximately 2 × 107 viable PC3 and Du145 cells containing the TMEM135-CCDC67 breakpoint or control vector, suspended in 0.2 ml of Hanks' balanced salt solution (Krackeler Scientific) were subcutaneously implanted in the abdominal flanks of 48 SCID mice to generate one tumor per mouse. The breakdown of the treated groups was as follows: six mice for PC3 cells transformed with pCMV-BP and treated with pAD5-Cas9 D10A -gRNA TMEM135int13 -gRNA CCDC67int9 and pAD-TMEM135 int13 -EGFP-tk-CCDC67 int9 (Ad-TC) and ganciclovir; six mice for PC3 cells transformed with pCMV-BP and treated with Ad-TC and PBS (control); six mice for PC3 transformed with pCMVscript and treated with Ad-TC and ganciclovir (control); and six mice for PC3 transformed with pCMVscript and treated with Ad-TC and PBS (control). Similar grouping distributions were used for DU145-xenografted mice. Mice were observed daily, and body weights and tumor sizes were recorded weekly. Three weeks after xenografting, the mice were treated with Ad-TC (5 × 10 10 pfu) and ganciclovir (80 mg/kg) 3 times per week, as indicated in Figure 4 , through intraperitoneal injection. After 7 weeks, the mice treated with Ad-TC and ganciclovir were killed, and necropsies were performed. For mice treated with control reagents, necropsies were performed after the mice had died from the xenografted cancers. Serial sections of formalinfixed, paraffin-embedded lung, brain, liver, kidney, vertebra and lymph-node specimens were collected, stained with hematoxylin and eosin, and examined microscopically. The protocol for the animal experiments was approved by the Institutional Review Board of the University of Pittsburgh. For HUH7and HEP3B-xenografted tumor treatments, similar procedures were used,
